Regenerative market Target hospitals and clinics focusing on burns, chronic wounds, and reconstructive surgery with fish-skin regenerative grafts, highlighting reduced hospital length of stay and superior tissue regeneration data from recent conferences.

Unicorn advantage Leverage Kerecis’ unicorn status and recent Coloplast partnership to open co‑selling and distribution discussions, emphasizing scale, credibility, and access to broader healthcare networks.

Clinical evidence Prioritize opportunities that can showcase new clinical data on intact fish-skin grafts reducing hospital stay and improving graft outcomes at major conferences and in peer‑reviewed publications.

Global reach Explore multinational and large‑volume accounts in medical device and regenerative medicine spaces, aligning with Kerecis’ Icelandic origin and expanding international presence to drive adoption in diverse markets.

Tech and compliance Position solutions to integrate with healthcare IT, HIPAA compliant workflows, and digital marketing for adoption in hospitals, facilitating smoother procurement and evidence-based decision making.